Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prodrug

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30 result(s) found for: Prodrug. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2018-000995-14 Sponsor Protocol Number: MIV-818-101/201 Start Date*: 2018-08-10
    Sponsor Name:Medivir AB
    Full Title: A Phase 1/2a Study in 3 Parts (Phase 1a and Phase 1b - Dose Escalations and Phase 2a Expansion Cohorts) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of...
    Medical condition: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), or, metastatic liver disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073077 Intrahepatic cholangiocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027479 Metastatic liver carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008258-21 Sponsor Protocol Number: NV20536 eu Start Date*: 2009-03-30
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegas...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) ES (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006604-11 Sponsor Protocol Number: NV19865 Start Date*: 2007-12-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) when given in combination with Pegasys...
    Medical condition: Chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007307-91 Sponsor Protocol Number: H8Y-MC-HBBR Start Date*: 2009-09-10
    Sponsor Name:Eli Lilly and Company
    Full Title: A Long-Term, Phase 2, Multicenter, Randomized, Open-Label, Comparative Safety Study of LY2140023 Versus Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-007647-14 Sponsor Protocol Number: Nabu1A2 Start Date*: 2009-01-07
    Sponsor Name:Turku University Hospital
    Full Title: The effect of fluvoxamine and ciprofloxacin on the pharmacokinetics and pharmacodynamics of nabumetone: A three-phase double-blind placebo-controlled cross-over study.
    Medical condition: Pharmacokinetics and pharmacodynamics, healthy volunteer trial
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003125-24 Sponsor Protocol Number: Clopidogrel_NSTEACS Start Date*: 2012-09-24
    Sponsor Name:A.O. UNIVERSITARIA INTEGRATA DI VERONA
    Full Title: Evaluation of platelet functional response in relation to the bioavailability of clopidogrel in patients with acute coronary syndromes without ST-segment elevation (NSTEACS).
    Medical condition: Patients with acute coronary syndromes without ST-segment elevation (NSTEACS).
    Disease: Version SOC Term Classification Code Term Level
    15.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016245-26 Sponsor Protocol Number: H8Y-MC-HBCO Start Date*: 2010-02-02
    Sponsor Name:Lilly S.A
    Full Title: Estudio de Fase 2, de 17 Semanas, Multicéntrico, Aleatorizado y Doble Ciego, Sobre la Eficacia de LY2140023 Combinado con Tratamiento Clínico Habitual Comparado con Placebo Combinado con Tratamient...
    Medical condition: Esquizofrenia
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003218-33 Sponsor Protocol Number: Clopidogrel-1-CPH Start Date*: 2008-03-10
    Sponsor Name:Blood bank, Rigshospitalet, University Hospital of Copenhagen
    Full Title: Antitrombotisk effekt af ADP receptor inhibitor i tillæg til Aspirin til hyperkoagulable patienter der gennemgår CABG kirurgi.
    Medical condition: Patients with coronary syndrome undergoing CABG in cardiopulmonary bypass receiving postoperative treatment with aspirin alone
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051592 Acute coronary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002149-36 Sponsor Protocol Number: G-202-002 Start Date*: 2012-12-10
    Sponsor Name:GenSpera, Inc.
    Full Title: An Open-Label, Single-Arm, Phase 2 Study of G-202 in Patients with Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer
    Medical condition: chemotherapy-naïve metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019585-90 Sponsor Protocol Number: WV21913 Start Date*: 2011-05-05
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus®, in Com...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2010-020171-23 Sponsor Protocol Number: 4SC-201-3-2010 Start Date*: 2010-10-04
    Sponsor Name:4SC AG
    Full Title: A phase I/II study to evaluate safety, tolerability, pharmacokinetics and efficacy of resminostat (4SC-201) in combination with a second-line treatment in patients with k-ras mutated advanced color...
    Medical condition: Advanced or metastasized colorectal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004864 10010036 Colorectal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002715-28 Sponsor Protocol Number: NV27779 Start Date*: 2011-12-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION WITH TELAPRE...
    Medical condition: Chronic Hepatitis C (CHC), Genotype 1
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022067-35 Sponsor Protocol Number: PP25213 Start Date*: 2011-02-17
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: INFORM-SVR: A Randomized, Multi-Center Study of Interferon-Free Treatment with a Combination of a Polymerase Inhibitor (RO5024048) and a Ritonavir boosted HCV Protease Inhibitor (RO5190591/r, DNV/...
    Medical condition: Chronic Hepatitis C (CHC) Genotype 1 (Arms A and B) and Genotypes 1b and 4 (Arm C)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002714-37 Sponsor Protocol Number: NV27780 Start Date*: 2011-11-07
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION WITH BOCEPREVIR...
    Medical condition: Chronic Hepatitis C (CHC), Genotype 1
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007727-41 Sponsor Protocol Number: DTS-201CLI002 Start Date*: 2008-04-29
    Sponsor Name:Diatos S.A.
    Full Title: An open-label, one arm, multi-centre Phase II trial evaluating the efficacy and safety of DTS-201 as a second-line chemotherapy in patients with hormone refractory prostate cancer
    Medical condition: Hormone refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing) BE (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001145-11 Sponsor Protocol Number: TransCon_hGH_CT-301 Start Date*: 2018-02-12
    Sponsor Name:Ascendis Pharma Endocrinology Division A/S
    Full Title: A multicenter, Phase 3, randomized, open-label, active-controlled, parallel-group trial investigating the safety, tolerability, and efficacy of TransCon hGH administered once a week versus standard...
    Medical condition: Growth hormone deficiency (GHD) in prepubertal children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) BG (Completed) PL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003976-11 Sponsor Protocol Number: HSG-1-13 Start Date*: 2014-01-24
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Effects of S-1 and capecitabine in combination with oxaliplatin on the coronary artery blood flow in patients metastatic gastrointestinal tract adenocarcinoma
    Medical condition: Metastatic gastrointestinal tract adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004129-28 Sponsor Protocol Number: NP27946 Start Date*: 2012-01-24
    Sponsor Name:F. Hoffmann-La Roche
    Full Title: Study To Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted DANOPREVIR in Combination With Peginterferon Alfa-2a Plus Ribavirin in Treatment-naive Patients ...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-003550-88 Sponsor Protocol Number: TMV-018-101 Start Date*: 2020-07-03
    Sponsor Name:Themis Bioscience GmbH
    Full Title: Full title of the trial: A Phase I/II open-label, dose-escalation, safety, clinical activity, pharmacokinetic and pharmacodynamic study of intra-tumoral application of TMV-018 in combination with 5...
    Medical condition: Patients with histologically confirmed diagnosis of colorectal carcinoma (left-sided or rectal), esophageal carcinoma, or gastric cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10062240 Tumor vaccine therapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004927-11 Sponsor Protocol Number: INNO-206-P2-STS-01 Start Date*: 2012-03-02
    Sponsor Name:CytRx Corporation
    Full Title: A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects with Metastatic, Locally A...
    Medical condition: Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041298 Soft tissue sarcomas histology unspecified HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 03 05:33:37 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA